伊维菌素治疗与住院COVID-19患者较低死亡率相关:伊维菌素在COVID-19中的研究
该研究回顾了2020年3月15日至5月11日在佛罗里达州四家Broward Health医院连续住院的280例确诊COVID-19患者,其中173例接受伊维菌素治疗、107例未接受。主要终点为全因院内死亡。单因素分析显示伊维菌素组死亡率较低(15.0% vs 25.2%,OR 0.52,95%CI 0.29-0.96,P=.03),在严重肺部受累患者中死亡率差异更明显(38.8% vs 80.7%,OR 0.15,95%CI 0.05-0.47,P=.001)。多因素调整后死亡率差异仍显著(OR 0.27,95%CI 0.09-0.80,P=.03);倾向匹配队列196例中伊维菌素组死亡率显著较低(13.3% vs 24.5%,OR 0.47,95%CI 0.22-0.99,P<.05),绝对风险降低11.2%(95%CI 0.38%-22.1%),需治疗人数8.9(95%CI 4.5-263)。拔管率和住院时间无显著差异。作者结论认为伊维菌素治疗与较低死亡率相关,尤其严重肺部受累者,但需随机对照试验确认。
要点
- 住院COVID-19患者中,伊维菌素组院内死亡率15.0% vs 未用组25.2%(OR 0.52,95%CI 0.29-0.96,P=.03)。
- 严重肺部受累(入组时需Fio2≥50%、无创或有创通气)患者中,伊维菌素组死亡率38.8% vs 80.7%(OR 0.15,95%CI 0.05-0.47,P=.001)。
- 倾向匹配队列196例中,伊维菌素组死亡率13.3% vs 24.5%(OR 0.47,95%CI 0.22-0.99,P<.05),绝对风险降低11.2%(95%CI 0.38%-22.1%),需治疗人数8.9(95%CI 4.5-263)。
- 拔管率(36.1% vs 15.4%,OR 3.11,95%CI 0.88-11.00,P=.07)和住院时间无显著差异。
- 作者结论认为伊维菌素治疗与较低死亡率相关,尤其严重肺部受累者,但需随机对照试验确认。
适用人群与场景
- 2020年3月15日至5月11日在佛罗里达州四家Broward Health医院连续住院的确诊COVID-19患者,共280例(伊维菌素组173例,未用组107例)。
- 严重肺部受累定义为入组时需Fio2≥50%、无创通气或有创通气。
诊断标准与关键阈值
- 严重肺部受累定义:入组时需Fio2≥50%、无创通气或有创通气。
处置流程与药物剂量
- 医院提供了伊维菌素用药指南,但治疗决策由主治医师自行决定;原文未写明具体剂量、给药途径和疗程。
- 多数患者同时接受羟氯喹、阿奇霉素或两者。
研究设计与关键结果
- 回顾性队列研究,纳入四家Broward Health医院连续住院的280例确诊COVID-19患者,伊维菌素组173例 vs 未用组107例。
- 主要终点全因院内死亡:单因素分析伊维菌素组15.0% vs 未用组25.2%(OR 0.52,95%CI 0.29-0.96,P=.03)。
- 严重肺部受累患者死亡率:伊维菌素组38.8% vs 未用组80.7%(OR 0.15,95%CI 0.05-0.47,P=.001)。
- 拔管率:伊维菌素组36.1% vs 未用组15.4%(OR 3.11,95%CI 0.88-11.00,P=.07),无显著差异;住院时间无显著差异。
- 多因素调整混杂因素和死亡风险后,死亡率差异仍显著(OR 0.27,95%CI 0.09-0.80,P=.03)。
- 倾向匹配队列196例中,伊维菌素组死亡率13.3% vs 未用组24.5%(OR 0.47,95%CI 0.22-0.99,P<.05),绝对风险降低11.2%(95%CI 0.38%-22.1%),需治疗人数8.9(95%CI 4.5-263)。
证据类型、等级与局限
- 证据类型:回顾性队列研究(连续住院患者病历回顾),采用logistic回归和倾向评分匹配调整混杂因素。
- 局限:原文未报告局限性。
- 作者结论:伊维菌素治疗与较低死亡率相关,尤其严重肺部受累患者;需随机对照试验确认这些发现。
对床旁实践的改变
- 该回顾性队列提示住院COVID-19患者使用伊维菌素与较低院内死亡率相关,尤其严重肺部受累者;作者认为需随机对照试验确认这些发现。
- 原文未给出伊维菌素的具体剂量、给药途径和疗程,治疗决策由主治医师自行决定。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Ivermectin was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro, which has led to off-label use, but clinical efficacy has not been described previously.
RESEARCH QUESTION: Does ivermectin benefit hospitalized coronavirus disease 2019 (COVID-19) patients?
STUDY DESIGN AND METHODS: Charts of consecutive patients hospitalized at four Broward Health hospitals in Florida with confirmed COVID-19 between March 15 and May 11, 2020, treated with or without ivermectin were reviewed. Hospital ivermectin dosing guidelines were provided, but treatment decisions were at the treating physician's discretion. The primary outcome was all-cause in-hospital mortality. Secondary outcomes included mortality in patients with severe pulmonary involvement, extubation rates for mechanically ventilated patients, and length of stay. Severe pulmonary involvement was defined as need for Fio2 ≥ 50%, noninvasive ventilation, or invasive ventilation at study entry. Logistic regression and propensity score matching were used to adjust for confounders.
RESULTS: Two hundred eighty patients, 173 treated with ivermectin and 107 without ivermectin, were reviewed. Most patients in both groups also received hydroxychloroquine, azithromycin, or both. Univariate analysis showed lower mortality in the ivermectin group (15.0% vs 25.2%; OR, 0.52; 95% CI, 0.29-0.96; P = .03). Mortality also was lower among ivermectin-treated patients with severe pulmonary involvement (38.8% vs 80.7%; OR, 0.15; 95% CI, 0.05-0.47; P = .001). No significant differences were found in extubation rates (36.1% vs 15.4%; OR, 3.11; 95% CI, 0.88-11.00; P = .07) or length of stay. After multivariate adjustment for confounders and mortality risks, the mortality difference remained significant (OR, 0.27; 95% CI, 0.09-0.80; P = .03). One hundred ninety-six patients were included in the propensity-matched cohort. Mortality was significantly lower in the ivermectin group (13.3% vs 24.5%; OR, 0.47; 95% CI, 0.22-0.99; P < .05), an 11.2% (95% CI, 0.38%-22.1%) absolute risk reduction, with a number needed to treat of 8.9 (95% CI, 4.5-263).
INTERPRETATION: Ivermectin treatment was associated with lower mortality during treatment of COVID-19, especially in patients with severe pulmonary involvement. Randomized controlled trials are needed to confirm these findings.
参考来源
- Rajter JC, Sherman MS, Fatteh N, et al. Use of Ivermectin Is Associated With Lower Mortality in Hospitalized Patients With Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. Chest. 2020. PMID: 33065103. doi:10.1016/j.chest.2020.10.009
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。